6-Sulfatoxymelatonin predicts treatment response to fluoxetine in major depressive disorder

Background: To date, no biomarker has been able to predict antidepressant response at an early blockade of norepinephrine or serotonin uptake. The transient nocturnal increase in plasma melatonin levels is upregulated by blocking these uptakes. The aim of this study was to test whether fluoxetine increase in urinary 6-sulfatoxymelatonin (aMT6s) is an indicator of serotonin uptake blockade. Methods: A total of 20 women (35–45 years of age) recruited from the community had a diagnosis of major depressive disorder confirmed by the Structured Clinical Interview for DSM-IV. Depressive symptoms were evaluated by the Beck Depression Inventory (BDI). Participants were instructed to take 20 mg of fluoxetine every morning. Every 4 weeks, the dose could be increased by 20 mg until symptom remission. The concentration of aMT6s was evaluated in overnight urine samples collected 1 day before and 1 day after the first fluoxetine dose. Results: An increase in aMT6s correlated to a decrease in BDI score evaluated on day 45 (ρ = −0.67, p = 0.024) was observed. Conclusions: Nocturnal increase in urinary aMT6s after the first day of medication use links the early mechanism of action of fluoxetine to its clinical output 45 days later. Thus, the relationship between urinary aMT6s excretion 1 day before/1 day after is a biomarker for predicting clinical output earlier, reducing illness burden and health care costs.

Download Full-text

The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder

Journal of Affective Disorders ◽

10.1016/j.jad.2021.03.036 ◽

2021 ◽

Author(s):

Xiaofeng Lan ◽

Yanling Zhou ◽

Fengchun Wu ◽

Kai Wu ◽

Yanni Zhan ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

First Episode ◽

Antidepressant Response ◽

Major Depressive ◽

Plasma Cytokine ◽

Cytokine Levels ◽

The Relationship

Download Full-text

Study of the relationship between episodic memory performance and hippocampal subfield volumes in major depressive disorder

PsycEXTRA Dataset ◽

10.1037/e534982014-059 ◽

2013 ◽

Author(s):

N. V. Malykhin ◽

S. Travis ◽

Y. Huang ◽

N. J. Coupland ◽

P. Silverstone ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Episodic Memory ◽

Memory Performance ◽

Major Depressive ◽

The Relationship

Download Full-text

The relationship of olfactory function and clinical traits in major depressive disorder

Behavioural Brain Research ◽

10.1016/j.bbr.2020.112594 ◽

2020 ◽

Vol 386 ◽

pp. 112594

Author(s):

Fang Wang ◽

Xiaohui Wu ◽

Jerry Gao ◽

Yongchao Li ◽

Yuncheng Zhu ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Olfactory Function ◽

Major Depressive ◽

Relationship Of ◽

The Relationship

Download Full-text

The relationship between loneliness and working-memory-related frontoparietal network connectivity in people with major depressive disorder

Behavioural Brain Research ◽

10.1016/j.bbr.2020.112776 ◽

2020 ◽

Vol 393 ◽

pp. 112776

Author(s):

Mengxia Gao ◽

Robin Shao ◽

Chih-Mao Huang ◽

Ho-Ling Liu ◽

Yao-Liang Chen ◽

...

Keyword(s):

Working Memory ◽

Major Depressive Disorder ◽

Depressive Disorder ◽

Network Connectivity ◽

Major Depressive ◽

Frontoparietal Network ◽

The Relationship

Download Full-text

Twelve-month prevalence and disability of DSM-IV bipolar disorder in an Australian general population survey

Psychological Medicine ◽

10.1017/s0033291703001636 ◽

2004 ◽

Vol 34 (5) ◽

pp. 777-785 ◽

Cited By ~ 99

Author(s):

P. B. MITCHELL ◽

T. SLADE ◽

G. ANDREWS

Keyword(s):

Bipolar Disorder ◽

Major Depressive Disorder ◽

Depressive Disorder ◽

National Survey ◽

Large Scale ◽

Well Being ◽

Major Depressive ◽

Co Morbidity ◽

Dsm Iv ◽

Days Out Of Role

Background. There have been few large-scale epidemiological studies which have examined the prevalence of bipolar disorder. The authors report 12-month prevalence data for DSM-IV bipolar disorder from the Australian National Survey of Mental Health and Well-Being.Method. The broad methodology of the Australian National Survey has been described previously. Ten thousand, six hundred and forty-one people participated. The 12-month prevalence of euphoric bipolar disorder (I and II) – similar to the euphoric-grandiose syndrome of Kessler and co-workers – was determined. Those so identified were compared with subjects with major depressive disorder and the rest of the sample, on rates of co-morbidity with anxiety and substance use disorders as well as demographic features and measures of disability and service utilization. Polychotomous logistic regression was used to study the relationship between the three samples and these dependent variables.Results. There was a 12-month prevalence of 0·5% for bipolar disorder. Compared with subjects with major depressive disorder, those with bipolar disorder were distinguished by a more equal gender ratio; a greater likelihood of being widowed, separated or divorced; higher rates of drug abuse or dependence; greater disability as measured by days out of role; increased rates of treatment with medicines; and higher lifetime rates of suicide attempts.Conclusions. This large national survey highlights the marked functional impairment caused by bipolar disorder, even when compared with major depressive disorder.

Download Full-text

Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatment

CNS Spectrums ◽

10.1017/s1092852912000430 ◽

2012 ◽

Vol 17 (2) ◽

pp. 76-86 ◽

Cited By ~ 11

Author(s):

David Mischoulon ◽

Stefania Lamon-Fava ◽

Jacob Selhub ◽

Judith Katz ◽

George I. Papakostas ◽

...

Keyword(s):

Major Depressive Disorder ◽

Depressive Disorder ◽

Mthfr C677t ◽

Response Rates ◽

Mthfr Gene ◽

Methionine Synthase ◽

Antidepressant Response ◽

Major Depressive ◽

Fluoxetine Treatment ◽

Intent To Treat

AbstractObjectiveTo examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response.MethodsWe screened 224 subjects (52% female, mean age 39 ± 11 years) with SCID-diagnosed major depressive disorder (MDD), and obtained 194 genetic samples. 49 subjects (49% female, mean age 36 ± 11 years) participated in a 12-week open clinical trial of fluoxetine 20–60 mg/day. Association between clinical response and C677T and A2756G polymorphisms, folate, B12, and homocysteine was examined.ResultsPrevalence of the C677T and A2756G polymorphisms was consistent with previous reports (C/C = 41%, C/T = 47%, T/T = 11%, A/A = 66%, A/G = 29%, G/G = 4%). In the fluoxetine-treated subsample (n = 49), intent-to-treat (ITT) response rates were 47% for C/C subjects and 46% for pooled C/T and T/T subjects (nonsignificant). ITT response rates were 38% for A/A subjects and 60% for A/G subjects (nonsignificant), with no subjects exhibiting the G/G homozygote. Mean baseline plasma B12 was significantly lower in A/G subjects compared to A/A, but folate and homocysteine levels were not affected by genetic status. Plasma folate was negatively associated with treatment response.ConclusionThe C677T and A2756G polymorphisms did not significantly affect antidepressant response. These preliminary findings require replication in larger samples.

Download Full-text